I le masina o Mati 2017, na faamaonia ai e le FDA le ocrelizumab, o se anti-CD20 monoclonal antibody, e avea o se togafitiga mo le RMS, faatasi ai ma manaʻoga mo le tele o suʻesuʻega o le Vaega IV. I le RMS, o loʻo latou faʻaititia ai le numera o osofaʻiga. O le interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, ocrelizumab, siponimod, ma cladribine. O le aʻafiaga o le togafitiga o le faʻamaʻi muamua e leʻi faʻamaʻaina i se taimi umi ona o le faʻaaogaina o le vailaʻau faʻamaʻi muamua e faʻaaogaina e faʻaitiitia ai le faʻafitauli o le faʻamaʻi o le faʻamaʻi o le faʻamaʻi o le faʻamaʻi o le faʻamaʻi o le faʻama
faʻamaʻi pipisi